WALTHAM, MA • 2022-11-03

BostonGene Announces Abstract Presentation at the Association for Molecular Pathology 2022 Annual Meeting

5 min to read

BostonGene to Showcase Cancer Diagnostic and Treatment Recommendation Test
WALTHAM, MA, November 3, 2022

BostonGene today announced that an abstract has been accepted for online publication for the Association for Molecular Pathology (AMP) 2022 Annual Meeting & Expo, which will be held November 3 - 5, 2022, at the Phoenix Convention Center in Phoenix, AZ.  BostonGene will also exhibit at booth 943.

The abstract, Co-occurrence of KRAS Q61K with Synonymous Mutations and Their Effect on RNA Expression, demonstrates the value of next-generation sequencing (NGS) in identifying the co-occurrence of KRAS p.Q61K with synonymous mutations and underscores the importance of RNA sequencing (RNA-seq) to further analyze their effects on gene expression and isoform composition.  The research, conducted with Massachusetts General Hospital, will be available online only in The Journal of Molecular Diagnostics.

BostonGene will showcase its innovative AI-based molecular and immune profiling platform for the discovery of significant correlations among tumor genomics, a patient’s immune system and the effectiveness of all available approved and investigational treatments, which leads to advances in personalized medicine and dramatically improved patients clinical outcomes. The BostonGene Tumor PortraitTM test uses DNA whole exome (WES) and RNA transcriptome (RNAseq) sequencing to detect genomic alterations such as single nucleotide variants (SNVs), indels, copy number alterations (CNAs), tumor mutational burden (TMB), microsatellite instability (MSI), expressed fusions, and frameshifts, and interrogates the expression levels of more than 20,000 genes, to identify actionable targets to inform treatment decision-making.

Please visit the AMP 2022 Annual Meeting & Expo website for more information.

About BostonGene Corporation

BostonGene is a company at the intersection of technology and biology, dedicated to advancing and personalizing cancer medicine. Founded in 2015, BostonGene has continually pushed the boundaries of innovation to improve cancer patient care and accelerate research and drug development through cutting-edge solutions. Leveraging our AI-powered multiomics platform, we digitize and comprehensively analyze the molecular profiles of cancer patients, including the immune system and tumor microenvironment. Our software solutions, indication-specific cancer library and advanced bioanalytics, enable us to discover multiparametric signatures, identify targets, match them to relevant indications for biopharma and recommend the most effective treatments for patients. For more information, visit www.BostonGene.com.

Erin Keleher O'Reilly

Senior Director